


Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!

International Journal of
Immunopathology and Pharmacology
Volume 34: 1–3
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2058738420941754
journals.sagepub.com/home/iji


Andrea Ciorba¹ , Virginia Corazzi¹, Piotr Henryk Skarżyński^{2,3,4},
Magdalena B Skarżyńska^{2,4}, Chiara Bianchini¹,
Stefano Pelucchi¹ and Stavros Hatzopoulos¹

Abstract

Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.

Keywords

chloroquine, favipiravir, hydroxychloroquine, lopinavir, ototoxicity, remdesivir, SARS-CoV-2 (Covid-19) pandemic

Date received: 13 May 2020; accepted: 19 June 2020

Dear Editor,

In this particular time where the SARS-CoV-2 pandemic has been reported to all clinical realities globally, we would like to remind clinical professionals to be aware of ototoxic side effects, a well-known issue back in vogue, due to the recent use of specific drugs against the new virus. Ototoxicity not only contributes to sensorineural hearing loss, tinnitus, or imbalance, but potentially impacts considerably the quality of life (QoL). In fact, it is well documented that hearing loss, tinnitus, and persistent imbalance retain a negative effect on mental well-being and QoL, having a strong association with the onset and the sustaining of depression and self-isolation.¹

Ototoxicity is a feature shared among some of the drugs proposed for the SARS-CoV-2 treatment. In particular, chloroquine and hydroxychloroquine have been widely promoted and used during the pandemic;^{2,3} however, in the past, data in the literature have suggested that in many treated cases side effects such as sensorineural

hearing loss, tinnitus, and/or persistent imbalance were common. Unfortunately, the latter are rarely reversible especially if developed after a drug usage of weeks or months.⁴

Azithromycin, a macrolide, has been administered often in combination with hydroxychloroquine, reinforcing its action, in SARS-CoV-2 patients. It has also been reported to cause both reversible and irreversible sensorineural hearing loss and tinnitus.⁵

Remdesivir and favipiravir are antiviral adenosine nucleotide analogues which are reported as

¹ENT & Audiology Department, University Hospital of Ferrara, Ferrara, Italy

²Institute of Physiology and Pathology of Hearing, Warsaw, Poland

³Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland

⁴Institute of Sensory Organs, Kajetany, Poland

Corresponding author:

Andrea Ciorba, ENT & Audiology Department, University Hospital of Ferrara, via A. Moro 8, loc Cona, Ferrara 44124, Italy.
Email: andrea.ciorba@unife.it



possible useful treatments against SARS-CoV-2. However, ototoxicity has been reported among the possible side effects of the adenosine nucleotide analogues;^{5,6} specifically, data in the literature report that patients may develop irreversible unilateral or bilateral hearing loss and tinnitus due to the use of these drugs, usually after a few weeks of administration.^{7,8}

Lopinavir, a nucleoside reverse-transcriptase inhibitor, proposed in the treatment of SARS-CoV-2 infections, has been related to the onset of sensorineural hearing loss,⁹ after several weeks of administration. Data in the literature also verify the ototoxic effects of lopinavir in vitro.¹⁰

In case of ototoxicity, the severity of hearing loss, tinnitus, or imbalance are usually influenced by the dose, the duration of the therapy, and other factors related to the patient (i.e. concomitant diseases and use of other medications). In most cases, the ototoxic effects develop after the persistent use of a medication over weeks or months. The etiology of the ototoxicity, the precise mechanisms which mediate inner ear hair cell damage, still remain unknown in many cases. Furthermore, the data in the literature do not offer information on the possible ototoxic synergetic effects, when treatments are administered in combination or consecutively. Currently, ototoxicity as a result of the interaction of the aforementioned specific drugs has not been fully investigated.¹¹

Another major drawback is the difficulty of monitoring hearing threshold shifts, while maintaining social distancing, during the pandemic. Since SARS-CoV-2 patients are completely isolated when sick, there is no possibility of monitoring their hearing level accurately as in an audiometric setting. Possible solutions (i.e. remote hearing level measurements) could relate to a tele-audiology model, but this technology is not adequately and widely developed so far.¹¹

Finally, it is necessary to consider that SARS-CoV-2 could potentially target directly the inner ear, as many other viruses, that is, HSV and VZV.¹² The data in the literature offering information on this topic are rather scarce.^{13,14}

Furthermore, cochlear hair cells have a high metabolic activity and are particularly vulnerable to hypoxic or ischemic damage.¹⁵ This scenario

is also probable in the SARS-CoV-2 patients where the inner ear can be damaged indirectly, due to the presence of persistent hypoventilation and hypoxigenation.

In conclusion, it is necessary to strictly monitor the use of such drugs, since the ototoxic hearing loss and/or tinnitus can be irreversible.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Andrea Ciorba  <https://orcid.org/0000-0003-3455-2295>

References

1. Pearson SE, Taylor J, Patel P, et al. (2019) Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: A narrative synthesis systematic review. *International Journal of Audiology* 58(11): 685–695.
2. COVID-19 Treatment Guidelines Panel. *Coronavirus diseases 2019 (COVID-19) treatment guidelines*. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/> (accessed 11 May 2020).
3. Cortegiani A, Ingoglia G, Ippolito M, et al. (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *Journal of Critical Care* 57: 279–283.
4. Bortoli R and Santiago M (2007) Chloroquine ototoxicity. *Clinical Rheumatology* 26(11): 1809–1810.
5. Cianfrone G, Pentangelo D, Cianfrone F, et al. (2011) Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: A reasoned and updated guide. *European Reviews for Medical and Pharmacological Sciences* 15: 601–636.
6. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. *Clinical Therapeutics* 22(6): 685–708.
7. Elfiky AA (2020) Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences* 253: 117592.
8. Formann E, Stauber R, Denk DM, et al. (2004) Sudden hearing loss in patients with chronic hepatitis C treated

- with pegylated interferon/ribavirin. *American Journal of Gastroenterology* 99(5): 873–877.
9. Williams B (2001) Ototoxicity may be associated with protease inhibitor therapy. *Clinical Infectious Diseases* 33(12): 2100–2102.
 10. Thein P, Kalinec GM, Park C, et al. (2014) In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity. *Hearing Research* 310: 27–35.
 11. COVID-19: Considerations for treatments using quinine derivatives and other ototoxic compounds. Available at: <https://www.audiology.org/news/covid-19-considerations-treatments-using-quinine-derivatives-and-other-ototoxic-compounds>
 12. Cohen BE, Durstenfeld A and Roehm PC (2014) Viral causes of hearing loss: A review for hearing health professionals. *Trends in Hearing* 18: 1–17.
 13. Mustafa MWM (2020) Audiological profile of asymptomatic Covid-19 PCR-positive cases. *American Journal of Otolaryngology* 10: 102483.
 14. Sriwijitalai W and Wiwanitkit V (2020) Hearing loss and COVID-19: A note. *American Journal of Otolaryngology* 41(3): 102473.
 15. Aimoni C, Bianchini C, Borin M, et al. (2010) Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: A case-control study. *Audiology and Neurotology* 15(2): 111–115.